| Identification | Back Directory | [Name]
ANP 1-28, HUMAN | [CAS]
89213-87-6 | [Synonyms]
HANF
α-hANP
Carperitide
ANP 1-28, HUMAN
ANF 1-28, HUMAN
ANP HUMAN, 1-28
ahANF, Carperitide
ANP, ALPHA-, HUMAN
Carperitide Acetate
α-Atriopeptin【human】
Carperitide impurity
ALPHA-ANF (1-28), HUMAN
ANP 1-28, HUMAN USP/EP/BP
ANF (1-28), HUMAN, PORCINE
SLRRSSCFGGRMDRIGAQSGLGCNSFRY
[MET(O)12]-ANP (HUMAN, 1-28)
Carperitide(ANP(1-28)/human)
ALPHA-ANP [1-28] HUMAN, CANINE
Atrial natriuretic factor【human】
ATRIAL NATRIURETIC PEPTIDE HUMAN
Carperitide Acetate, carperitida
Carperitide / Carperitide Acetate
atrial natriuretic factor (99-126)
Atrial natriuretic peptide【porcine】
ATRIAL NATRIURETIC FACTOR 1-28, HUMAN
ATRIAL NATRIURETIC PEPTIDE HUMAN, 1-28
ATRIAL NATRIURETIC PEPTIDE 1-28, HUMAN
ALPHA-ATRIAL NATRIURETIC PEPTIDE, HUMAN
ATRIAL NATRIURETIC PEPTIDE, ALPHA-, HUMAN
Atrial natriureticpeptide-28 (huMan) (9CI)
ANP (HUMAN, 1-28) (PORCINE, BOVINE, CANINE)
ATRIAL NATRIURETIC FACTOR (1-28) (HUMAN, CANINE)
ATRIAL NATRIURETIC FACTOR (1-28) (HUMAN, PORCINE)
ATRIAL NATRIURETIC PEPTIDE (1-28), HUMAN, PORCINE
ALPHA-ATRIAL NATRIURETIC PEPTIDE, HUMAN, RECOMBINANT
SLRRSSCFGGRMDRIGAQSGLGCNSFRY (DISULFIDE BRIDGE: 7-23)
Atrial Natriuretic Factor (1-28) (huMan)
αhANF, Carperitide
[MET(O)12]-A-TYPE (ATRIAL) NATRIURETIC PEPTIDE (HUMAN, 1-28)
Atrial Natriuretic Factor (1-28) (human), αhANF, Carperitide
Atrial Natriuretic Peptide (1-28) (human) (trifluoroacetate salt)
A-TYPE (ATRIAL) NATRIURETIC PEPTIDE (HUMAN, 1-28) (PORCINE, BOVINE, CANINE)
SER-LEU-ARG-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-MET-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR
SER-LEU-ARG-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-MET(O)-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR
H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH
H-SER-LEU-ARG-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-MET-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR-OH (DISULFIDE BRIDGE: 7-23)
SER-LEU-ARG-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-MET: O-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR[SLRRSSCFGGR-MET: O-DRIGAQSGLGCNSFRY]DISULFIDE BRIDGE CYS7-CYS23.
Atrial Natriuretic Factor (1-28) (human) hydrochloride salt H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH hydrochloride salt (Disulfide bond)
L-Tyrosine, L-seryl-L-leucyl-L-arginyl-L-arginyl-L-seryl-L-seryl-L-cysteinyl-L-phenylalanylglycylglycyl-L-arginyl-L-methionyl-L-α-aspartyl-L-arginyl-L-isoleucylglycyl-L-alanyl-L-glutaminyl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-asparaginyl-L-seryl-L-phenylalanyl-L-arginyl-, cyclic (7→23)-disulfi... | [EINECS(EC#)]
686-482-9 | [Molecular Formula]
C127H203N45O39S3 | [MDL Number]
MFCD00076226 | [MOL File]
89213-87-6.mol | [Molecular Weight]
3080.44 |
| Chemical Properties | Back Directory | [density ]
1.55±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Water: 1 mg/ml | [form ]
A lyophilized powder | [Sequence]
H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH，(Disulfide bridge: Cys-Cys) | [InChIKey]
NSQLIUXCMFBZME-VUEHYBQXNA-N |
| Hazard Information | Back Directory | [Description]
Carperitide is the α-human atrial natriuretic peptide (α-hANP) produced by
recombinant technology. It was introduced in Japan as a treatment for acute
congestive heart failure (CHF). In dogs with CHF, carperitide significantly reduced the
elevated left ventricular end-diastolic pressure and the index of myocardial oxygen
consumption (systolic blood pressure x heart rate). In a clinical trial, carperitide was
effective in improving hemodynamics and symptoms in 60% of patients with acute CHF.
Carperitide was reported to be well tolerated with no significant adverse effects
clinically. A beneficial effect on hemodynamics has been reported in chronic heart
failure patients. Carperitide is also in clinical trials for maintenance of blood pressure
during surgical operations. | [Originator]
Suntory (Japan) | [Uses]
Treatment of decompensated congestive heart
failure. | [Definition]
ChEBI: Carperitide is a polypeptide. | [Brand name]
Daiichi Suntory, Japan. | [References]
[1] T.GEOFFREY FLYNN Adolfo J de B Mercedes L de Bold. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties[J]. Biochemical and biophysical research communications, 1983, 117 3: Pages 859-865. DOI: 10.1016/0006-291x(83)91675-3
[2] MAACK T. Role of atrial natriuretic factor in volume control[J]. Kidney international, 1996, 49 6: Pages 1732-1737. DOI: 10.1038/ki.1996.257
[3] YUKIO HIRATA. Specific receptors for atrial natriuretic factor (ANF) in cultured vascular smooth muscle cells of rat aorta[J]. Biochemical and biophysical research communications, 1984, 125 2: Pages 562-568. DOI: 10.1016/0006-291x(84)90576-x
[4] T. ISHIHARA. Vasodilatory and diuretic actions of α-human atrial natriuretic polypeptide (α-hANP)[J]. Life sciences, 1985, 36 12: Pages 1205-1215. DOI: 10.1016/0024-3205(85)90239-5
[5] KOMEI TANAKA. Long-term carperitide treatment attenuates left ventricular remodeling in rats with heart failure after autoimmune myocarditis.[J]. Journal of Cardiovascular Pharmacology, 2009: 232-239. DOI: 10.1097/fjc.0b013e3181b0cf50 |
|
|